Related Experiment Video
Updated: May 3, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelets in stroke prevention
Antonio Pinto, Domenico Di Raimondo, Antonino Tuttolomondo
1Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo, Palermo, Italy. domenico.diraimondo@unipa.it.
Insights
Long-term antiplatelet therapy significantly reduces vascular events by approximately 25% in high-risk patients, particularly for secondary stroke prevention. Current guidelines recommend its broad use, though primary prevention benefits are less clear.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Public Health
Background:
- Stroke is a leading global cause of death and disability.
- High recurrence rates necessitate long-term preventive strategies for at-risk individuals, especially those with atherosclerotic vascular disease.
Purpose of the Study:
- To evaluate the efficacy of antiplatelet therapy in reducing vascular events.
- To clarify the role of antiplatelet therapy in secondary stroke prevention for non-cardioembolic stroke and TIA.
- To assess the nuances of antiplatelet therapy in primary stroke prevention.
Main Methods:
- Review of existing clinical trials on antiplatelet drug use in ischemic stroke patients.
- Analysis of data regarding the reduction of vascular events (myocardial infarction, stroke, vascular death).
- Examination of guideline recommendations for stroke prevention.
Main Results:
- Antiplatelet therapy demonstrates an approximate 25% reduction in vascular events for high-risk patients.
- Strong evidence supports its use in secondary stroke prevention for non-cardioembolic stroke and TIA.
- The absolute benefits for primary prevention are generally lower and less defined.
Conclusions:
- Antiplatelet therapy is a cornerstone in secondary stroke prevention, significantly lowering vascular event risk.
- While established for secondary prevention, further research is needed to refine indications and understand benefits in primary prevention and specific patient subgroups.
Abstract:
Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic stroke or TIA. As for the primary prevention indications are less accurate because the absolute benefi ts of aspirin in reducing the happening of vascular events, are generally much lower than in secondary prevention. Although several trials have been investigated use of antiplatelet drugs in ischemic stroke patients, ascertaining the sure benefit, especially in secondary prevention in non-cardioembolic stroke, various issues remains unclarified, and new questions raises with the analysis of the results of available trials.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:27Peripheral Artery Disease III: Interprofessional Care